Difference between revisions of "Part:BBa K4156099"
(8 intermediate revisions by the same user not shown) | |||
Line 9: | Line 9: | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
− | pCadC-TP901 consists of a fusion of the pH-sensitive promoter pCadC and the serine integrase TP901. It will act as a complex regulatory for controlling downstream logic gates and transcription of genes. | + | pCadC-TP901 consists of a fusion of the pH-sensitive promoter pCadC (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156076"> BBa_K4156076 </a></html> ) and the serine integrase TP901 (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156087"> BBa_K4156087 </a></html> ). It will act as a complex regulatory for controlling downstream logic gates and transcription of genes. |
===Characterization=== | ===Characterization=== | ||
Line 16: | Line 16: | ||
==In vitro characterization and data analysis of the reported strains== | ==In vitro characterization and data analysis of the reported strains== | ||
− | To improve signaling stability as well as accuracy, we added Amplifying genetic switches based on serine integrase ( | + | To improve signaling stability as well as accuracy, we added Amplifying genetic switches based on serine integrase (TP901) to the R reporter(<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156118"> BBa_K4156118 </a></html> ) to construct the AR reporter. |
+ | |||
+ | Fig 1 indicates pH (pCadc) induced AR reporters with homogenized fluorescence intensity (mRFP/Cell). In contrast to Fig 1 and 2, the fluorescence intensity of the AR reporter appeared more stable over time at pH 7.3 and was higher than that of the R reporter at pH 5.8, 6.3, and 7.3. This result indicates that the addition of amplifying genetic switch enhances the reporter intensity and robustness of the lactate biosensor. | ||
<html> | <html> | ||
Line 32: | Line 34: | ||
</html> | </html> | ||
− | |||
− | + | We also observed the mRFP fluorescence intensity of WT 1917 and reporter strain AR(pLldR/pCadC/pPepT-Switch (TP901)-mRFP) after 48 h of induction using a fluorescence microscope (Olympus BX53). | |
+ | The results showed that the three promoters (pLldR, pCadC and pPepT)-Switch (TP901)-mRFP exhibited a uniform and clear red fluorescence signal after induction(Fig 3), indicating that the pLldR/pCadC/PepT-Switch (TP901) system could be expressed normally. | ||
+ | <html> | ||
+ | <figure style="text-align:center;"> | ||
+ | <img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/15-1.png" alt="control"> | ||
+ | <figcaption><b>Figure3:</b>Fluorescence intensity of engineered bacterias with pLldR/pCadC/pPepT-Switch (TP901)-mRFP , versus control EcN 1917 ,after 48h of induction.</figcaption> | ||
+ | </figure> | ||
+ | </html> | ||
+ | |||
+ | ==Lactate (pLldR) and pH (pCadC) Induced promoter-controlled effector engineered strain co-incubated with RKO cells== | ||
+ | We linked pCadC-TP901 to XOR gate-HlyE (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156119"> BBa_K4156119 </a></html>) for validation of treatment viability. | ||
+ | |||
+ | Figure 4 shows the RKO cell activity after incubation of each strain in fresh DMEM medium, normoxic conditions(OD=0.6, 30 μl, 3 hours). It can be seen that the RKO relative viability of the experimental groups with the addition of the effector strains in the fresh culture medium did not change significantly compared to the WT group, except for the plac+HlyE positive control. | ||
− | Figure | + | Figure 5 shows the RKO cell activity of each strain after incubation in 3 day DMEM medium, normoxic conditions. It can be concluded that in the 3 day DMEM medium, due to the accumulation of metabolites such as cellular lactate, the lactate promoter and pH promoter were activated in the engineered strains and started to synthesize therapeutic proteins, resulting in a decrease in the relative viability of RKO compared to the WT group, especially in the pCadC+switch+HlyE groups with the addition of the amplified gene switch. switch+HlyE group with the addition of the amplifying gene switch significantly reduced the RKO relative viability. In contrast, the decrease in RKO relative viability in the pCadC+φ174E+switch+HlyE group was not significant, probably due to the decrease in the number of bacteria and the decrease in the number of synthesized therapeutic proteins by the addition of lysis genes. |
<html> | <html> | ||
<figure style="text-align:center;"> | <figure style="text-align:center;"> | ||
<img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-1.png" alt="control"> | <img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-1.png" alt="control"> | ||
− | <figcaption><b>Figure | + | <figcaption><b>Figure 4:</b>The activity of RKO cells after incubation with each strain (OD=0.6, 30 μl, 3 hours) in fresh DMEM medium, normoxic conditions.</figcaption> |
</figure> | </figure> | ||
Line 48: | Line 61: | ||
<figure style="text-align:center;"> | <figure style="text-align:center;"> | ||
<img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-2.png" alt="control"> | <img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-2.png" alt="control"> | ||
− | <figcaption><b>Figure | + | <figcaption><b>Figure 5:</b>The activity of RKO cells after incubation with each strain (OD=0.6, 30 μl, 3 hours) in 3 day DMEM medium, normoxic conditions.</figcaption> |
</figure> | </figure> | ||
</html> | </html> | ||
==Coincubation of different doses of effector engineered strains (OD=0.6) with RKO cells== | ==Coincubation of different doses of effector engineered strains (OD=0.6) with RKO cells== | ||
− | Figure | + | We linked pCadC-TP901 to XOR gate-HlyE (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156119"> BBa_K4156119 </a></html>) for validation of treatment viability. |
+ | |||
+ | Figure 6 shows the RKO cell activity after incubation with different doses of plldR and pCadC control effector strains in 3 day DMEM medium, normoxic conditions. The RKO cell activity decreased with increasing doses of effector strains. | ||
<html> | <html> | ||
<figure style="text-align:center;"> | <figure style="text-align:center;"> | ||
<img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-3.png" alt="control"> | <img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-3.png" alt="control"> | ||
− | <figcaption><b>Figure | + | <figcaption><b>Figure 6:</b>The RKO cell activity after incubation with different doses of plldR and pCadC control effector strains under 3 day DMEM medium, normoxic conditions.</figcaption> |
</figure> | </figure> | ||
</html> | </html> | ||
+ | |||
==30 μl effector engineered strains (OD=0.6) were co-incubated with RKO cells for different times== | ==30 μl effector engineered strains (OD=0.6) were co-incubated with RKO cells for different times== | ||
− | Figure | + | We linked pCadC-TP901 to XOR gate-HlyE (<html><a style="padding: 0px; margin: 0px;" href="https://parts.igem.org/Part:BBa_K4156119"> BBa_K4156119 </a></html>) for validation of treatment viability. |
+ | |||
+ | Figure 7 shows the RKO cell activity after incubation of plldR and pCadC control effector strains for different times under 3 day DMEM medium, normoxic conditions. It can be seen that the RKO cell activity decreased with the increase of co-incubation time. | ||
<html> | <html> | ||
<figure style="text-align:center;"> | <figure style="text-align:center;"> | ||
<img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-4.png" alt="control"> | <img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/10-4.png" alt="control"> | ||
− | <figcaption><b>Figure | + | <figcaption><b>Figure 7:</b>The RKO cell activity after incubation of plldR and pCadC control effector strains for different times under 3 day DMEM medium, normoxic conditions..</figcaption> |
</figure> | </figure> | ||
</html> | </html> | ||
Line 75: | Line 93: | ||
<figure style="text-align:center;"> | <figure style="text-align:center;"> | ||
<img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/12-1.png" alt="control"> | <img style="max-width:700px;" src="https://static.igem.wiki/teams/4156/wiki/part/12-1.png" alt="control"> | ||
− | <figcaption><b>Figure | + | <figcaption><b>Figure 8:</b>Western blot result of HlyE under different promoter control</figcaption> |
</figure> | </figure> | ||
</html> | </html> |
Latest revision as of 07:31, 13 October 2022
pCadC-TP901
pCadC-TP901 is constructed with pH-sensitive promoter pCadC and serine integrase TP901.
Usage and Biology
pCadC-TP901 consists of a fusion of the pH-sensitive promoter pCadC ( BBa_K4156076 ) and the serine integrase TP901 ( BBa_K4156087 ). It will act as a complex regulatory for controlling downstream logic gates and transcription of genes.
Characterization
In vitro characterization and data analysis of the reported strains
To improve signaling stability as well as accuracy, we added Amplifying genetic switches based on serine integrase (TP901) to the R reporter( BBa_K4156118 ) to construct the AR reporter.
Fig 1 indicates pH (pCadc) induced AR reporters with homogenized fluorescence intensity (mRFP/Cell). In contrast to Fig 1 and 2, the fluorescence intensity of the AR reporter appeared more stable over time at pH 7.3 and was higher than that of the R reporter at pH 5.8, 6.3, and 7.3. This result indicates that the addition of amplifying genetic switch enhances the reporter intensity and robustness of the lactate biosensor.
We also observed the mRFP fluorescence intensity of WT 1917 and reporter strain AR(pLldR/pCadC/pPepT-Switch (TP901)-mRFP) after 48 h of induction using a fluorescence microscope (Olympus BX53).
The results showed that the three promoters (pLldR, pCadC and pPepT)-Switch (TP901)-mRFP exhibited a uniform and clear red fluorescence signal after induction(Fig 3), indicating that the pLldR/pCadC/PepT-Switch (TP901) system could be expressed normally.
Lactate (pLldR) and pH (pCadC) Induced promoter-controlled effector engineered strain co-incubated with RKO cells
We linked pCadC-TP901 to XOR gate-HlyE ( BBa_K4156119 ) for validation of treatment viability.
Figure 4 shows the RKO cell activity after incubation of each strain in fresh DMEM medium, normoxic conditions(OD=0.6, 30 μl, 3 hours). It can be seen that the RKO relative viability of the experimental groups with the addition of the effector strains in the fresh culture medium did not change significantly compared to the WT group, except for the plac+HlyE positive control.
Figure 5 shows the RKO cell activity of each strain after incubation in 3 day DMEM medium, normoxic conditions. It can be concluded that in the 3 day DMEM medium, due to the accumulation of metabolites such as cellular lactate, the lactate promoter and pH promoter were activated in the engineered strains and started to synthesize therapeutic proteins, resulting in a decrease in the relative viability of RKO compared to the WT group, especially in the pCadC+switch+HlyE groups with the addition of the amplified gene switch. switch+HlyE group with the addition of the amplifying gene switch significantly reduced the RKO relative viability. In contrast, the decrease in RKO relative viability in the pCadC+φ174E+switch+HlyE group was not significant, probably due to the decrease in the number of bacteria and the decrease in the number of synthesized therapeutic proteins by the addition of lysis genes.
Coincubation of different doses of effector engineered strains (OD=0.6) with RKO cells
We linked pCadC-TP901 to XOR gate-HlyE ( BBa_K4156119 ) for validation of treatment viability.
Figure 6 shows the RKO cell activity after incubation with different doses of plldR and pCadC control effector strains in 3 day DMEM medium, normoxic conditions. The RKO cell activity decreased with increasing doses of effector strains.
30 μl effector engineered strains (OD=0.6) were co-incubated with RKO cells for different times
We linked pCadC-TP901 to XOR gate-HlyE ( BBa_K4156119 ) for validation of treatment viability.
Figure 7 shows the RKO cell activity after incubation of plldR and pCadC control effector strains for different times under 3 day DMEM medium, normoxic conditions. It can be seen that the RKO cell activity decreased with the increase of co-incubation time.
Western blot
To verify the extracellular secretion of HlyE, we constructed an AE strain by fusing his tag at the C-terminus of HlyE. Then, the AE strain (HlyE with his tag) was inoculated in 50 ml of LB medium containing the corresponding antibiotics and cultured overnight at 37 °C. Then, 5 ml of the culture was centrifuged and the supernatant was collected. The supernatant was concentrated using the TCA precipitation method (25% TCA, -20°C, 1h) to isolate the total protein. Finally, the expression of HlyE was detected by western blot. The results showed that the constitutive promoter could secrete HlyE under both inducible and non-inducible conditions, while the lactate (plldR), pH (pCadc) and hypoxia (pPepT) inducible reporters could only secrete HlyE under inducible conditions and not under non-inducible conditions. indicated that our constructed AE strain could well cope with environmental induction and secrete HlyE in the tumor microenvironment It was shown that our AE strain could respond well to environmental induction and secrete HlyE in the tumor microenvironment, thus killing cancer cells without harming other normal cells.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal AgeI site found at 1632
- 1000COMPATIBLE WITH RFC[1000]